The ARCHITECT B12 assay is a chemiluminescent microparticle Intrinsic Factor assay for the quantitative determination of vitamin B12 in human serum on the ARCHITECT i System. Measurements obtained by this device are used in the diagnosis and treatment of anemias of gastrointestinal malabsorption.

The ARCHITECT B12 Controls are used for the estimation of test precision and the detection of systematic analytical deviations of the ARCHITECT i System when used for the quantitative determination of vitamin B12 in human serum when using the ARCHITECT B12 Reagent Kit.

The ARCHITECT B12 Calibrators are used to calibrate the ARCHITECT i System when the system is used for the quantitative determination of vitamin B12 in human serum using the ARCHITECT B12 Reagent Kit.

Device Description

The ARCHITECT B12 assay is a two-step assay with an automated sample pretreatment, for determining the presence of B12 in human serum using chemiluminescent microparticle immunoassay (CMIA) technology with flexible assay protocols, referred to as Chemiflex.

Sample and Pre-Treatment Reagent 1, Pre-Treatment Reagent 2, and Pre-Treatment Reagent 3 are combined. An aliquot of the pre-treated sample is aspirated and transferred into a new reactions vessel (RV). The pre-treated sample, assay diluent, and intrinsic factor coated paramagnetic microparticles are combined. B12 present in the sample binds to the intrinsic factor coated microparticles. After washing, B12 acridinium-labeled conjugate is added in the second step. Pre-Trigger and Trigger Solutions are then added to the reaction mixture; the resulting chemiluminescent reaction is measured as relative light units (RLUs). An inverse relationship exists between the amount of B12 in the sample and the RLUs' detected by the ARCHITECT i System optics.

AI/ML Overview

Acceptance Criteria and Device Performance Study for ARCHITECT B12 Assay

This document describes the acceptance criteria and the study conducted to demonstrate the substantial equivalence of the ARCHITECT B12 assay to a legally marketed predicate device.

1. Table of Acceptance Criteria and Reported Device Performance

The provided 510(k) summary does not explicitly state pre-defined acceptance criteria in terms of specific performance metrics (e.g., target accuracy, precision thresholds) that the ARCHITECT B12 assay needed to meet. Instead, the study aimed to demonstrate substantial equivalence to a predicate device. The performance was assessed through a comparison study.

Performance Metric (Implied)	Reported Device Performance
Agreement with Predicate Device (Correlation)	Equivalence demonstrated using current commercially available Roche Elecsys E170 Vitamin B12 reagents with 172 patient samples covering the range of 83 pg/mL to 2000 pg/mL.

Note: The 510(k) summary focuses on demonstrating equivalence rather than meeting specific numerical acceptance criteria for a new device type. The key acceptance was the FDA's determination of "substantial equivalence."

2. Sample Size and Data Provenance for the Test Set

Sample Size: 172 patient samples.
Data Provenance: Not explicitly stated, but based on the context of a medical device submission, these would typically be human serum samples. The geographical origin (e.g., country) is not specified. The study is implicitly retrospective as it involves testing archived patient samples against an existing predicate device.

3. Number of Experts and Qualifications for Ground Truth

Number of Experts: Not applicable. The ground truth for this type of assay comparison is established by the results of the legally marketed predicate device, not by expert interpretation.
Qualifications of Experts: Not applicable.

4. Adjudication Method for the Test Set

Adjudication Method: Not applicable. The comparison is objective, based on quantitative measurements from two different assay systems, rather than subjective interpretation requiring adjudication.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

MRMC Study: No, an MRMC comparative effectiveness study was not done. This type of study is typically used for diagnostic imaging devices where human readers interpret images. The ARCHITECT B12 assay is a quantitative in-vitro diagnostic test.
Effect Size of Human Reader Improvement with AI: Not applicable, as no MRMC study was performed.

6. Standalone (Algorithm Only) Performance Study

Standalone Study: Yes, the study described is a standalone performance study in the context of an in-vitro diagnostic device. The ARCHITECT B12 assay's performance was evaluated independently by comparing its results to a predicate device, without direct human-in-the-loop interpretation of the assay results themselves. The "algorithm" here refers to the entire assay system and its methodology.

7. Type of Ground Truth Used

Type of Ground Truth: The ground truth was established by the results obtained from the legally marketed predicate device, the Roche Elecsys E170 Vitamin B12 assay (K060755). This is considered the "gold standard" for comparison in demonstrating substantial equivalence for an in-vitro diagnostic device.

8. Sample Size for the Training Set

Sample Size: The 510(k) summary does not provide specific details about a "training set" for the ARCHITECT B12 assay in the context of machine learning or AI. In the development of an in-vitro diagnostic, calibration and validation samples are used during the development and manufacturing process, but these are distinct from a "training set" in an AI/ML context. The information provided focuses on the pivotal study for regulatory submission.

9. How Ground Truth for the Training Set Was Established

How Ground Truth Was Established (Training Set): As no specific training set in the AI/ML sense is described, the method for establishing its ground truth is not applicable in this document portion. For the overall assay, calibration materials are used, and their values are typically traceable to reference methods or primary standards, but this is a different concept than ground truth for a machine learning model.

Summary

{0}------------------------------------------------

K110579

OCT - 6 2011 Admin 3.0 510(k) Summary (Summary of Safety and Effectiveness)

This summary of the 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

Applicant Name

Darla Abano, Senior Regulatory Affairs Administrator Regulatory Affairs Abbott Laboratories Diagnostics Division Dept 9V6, AP5N-2 100 Abbott Park Road Abbott Park, IL 60064

Device Name

Reagents Classification Name: Vitamin B12 test system Trade Name: ARCHITECT B12 Common Name: B12 Governing Regulation: 862.1810 Device Classification: Class II Classification Panel: Clinical Chemistry Product Code: CDD

Calibrators

Classification Name: Calibrator Trade Name: ARCHITECT B12 Calibrators (A-F) Common Name: Calibrator Governing Regulation: 862.1150 Device Classification: Class II Classification Panel: Clinical Chemistry Product Code: JIT

Controls

Classification Name: Quality Control Material (assayed and unassayed) Trade Name: ARCHITECT B12 Controls (Low, Medium, and High) Common Name: Control Governing Regulation: 862.1660 Device Classification: Class I Classification Panel: Clinical Chemistry Product Code: JJX

{1}------------------------------------------------

Legally Marketed Device to Which Equivalence is Claimed

Roche Elecsys Vitamin B12 Immunoassay (K060755)

Intended Use of Device

The ARCHITECT B12 assay is a chemiluminescent microparticle Intrinsic Factor assay for the quantitative determination of vitamin B12 in human serum on the ARCHITECT i System.

Description of Device

Reagent Kit

Calibrators

{2}------------------------------------------------

Controls

Comparison of Technological Characteristics

The ARCHITECT B12 assay utilizes chemiluminescent microparticle immunoassay (CMIA) technology for the quantitative determination of vitamin B12 in human serum. The Roche Elecsys E170 Vitamin B12 assay utilizes technology for the quantitative determination of vitamin B12 in human serum and plasma on the E170 System.

Summary of Nonclinical Performance

The data presented in the pre-market notification demonstrate that the ARCHITECT B12 assay performs substantially equivalent to the predicate device, the Roche Elecsys E170 Vitamin B12 assay (K060755). Equivalence was demonstrated using the current commercially available Roche Elecsys E170 Vitamin B12 reagents with 172 patient samples covering the range of 83 pg/mL to 2000 pg/mL. The data presented in the premarket notification provide a reasonable assurance that the ARCHITECT B12 assay is safe and effective for the stated intended use.

{3}------------------------------------------------

Image /page/3/Picture/1 description: The image shows a circular logo for the U.S. Department of Health & Human Services. The logo features the department's name encircling a symbol. The symbol is a stylized depiction of an eagle or bird-like figure, with its wings spread in a dynamic, flowing manner.

10903 New Hampshire Avenue Silver Spring, MD 20993

Abbout Laboratories c/o Darla Abaño Dept 9V6. AP5N-2 100 Abbout Park Road Abbott Park. IL 60064

OCT - 6 2011

Re: K110579

Trade/Device Name: ARCHITECT B12 Reagent Kit, ARCHITECT B12 Controls, ARCHITECT B12 Calibrators Regulation Number: 21 CFR 862.1810 Regulation Name: Vitamin B12 Test System Regulatory Class: Class II Product Code: CDD. IIT. JJX Dated: August 30, 2011 Received: August 31. 2011

Dear Ms. Abaño:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug. and Cosmetic Act (Act) that do not require approval of a premarket anproval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

{4}------------------------------------------------

Page 2 -

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Virro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or ( 301) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/def.ault.htm.

Sincerely yours,

signature

Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

Indications for Use

510(k) Number (if known): K110579

Device Name: ARCHITECT B12 Reagent Kit, ARCHITECT B12 Controls, ARCHITECT B12 Calibrators

Indications for Use

Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR

Over-The-Counter Use (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE; CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

Buth Cheale

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety 510(k) 上川の579

Page 1 of 1

Regulation Number and Section

§ 862.1810 Vitamin B

12 test system.(a)
Identification. A vitamin B12 test system is a device intended to measure vitamin B12 in serum, plasma, and urine. Measurements obtained by this device are used in the diagnosis and treatment of anemias of gastrointestinal malabsorption.(b)
Classification. Class II.